ArticleFrontiers in immunology2026
CircZFYVE1 functions as a competitive endogenous RNA to enhance LSM14A-mediated antiviral defense against influenza A virus.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Circular RNAs (circRNAs) are covalently closed endogenous RNAs that regulate gene expression at the post transcriptional level and have been implicated in antiviral immunity. However, their functional roles and regulatory mechanisms during influenza A virus (IAV) infection remain incompletely defined. Methods: circZFYVE1 expression was profiled in A549 cells infected with the WSN strain of IAV using RT qPCR under time course and dose response conditions. The mechanistic function of circZFYVE1 was investigated through miRNA target prediction, luciferase reporter assays, and functional assays assessing its role as a competing endogenous RNA (ceRNA) and its impact on innate antiviral signaling. Results: circZFYVE1 expression was induced in a time and dose dependent manner following WSN infection. Mechanistically, circZFYVE1 acts as a ceRNA by sponging hsa miR 4435, thereby relieving miRNA mediated suppression of the processing body associated protein LSM14A and enhancing innate antiviral signaling during infection. Discussion: These findings define a circRNA-miRNA-mRNA regulatory axis that links IAV infection to innate antiviral responses, providing new insights into circRNA mediated host defenses. The circZFYVE1/LSM14A pathway represents a potential target for future studies aimed at modulating endogenous antiviral immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.